Cardiovascular risk comorbidities in rheumatoid arthritis patients and the use of anti-rheumatic drugs: a cross-sectional real-life study
Tóm tắt
Rheumatoid arthritis (RA) is a common autoimmune systemic inflammatory disease. In addition to joint involvement, RA patients frequently have other comorbidities, such as cardiovascular diseases. Drugs used for RA treatment may increase or decrease the risk of a cardiovascular event. This study aims to analyze cardiovascular risk comorbidities in patients with RA and the correlation with the use of anti-rheumatic drugs. Cross-sectional study conducted based on the real-life rheumatoid arthritis study database – REAL, a prospective observational cohort study. Associations between the use of anti-rheumatic drugs and the presence of comorbidities were represented by their prevalence ratio and evaluated using the Chi-square or Fisher’s Exact tests. We assessed 1116 patients, 89.4% women, mean age of 55.15 years and predominance of seropositive disease. 63.3% had some cardiovascular comorbidity, predominantly hypertension (49.9%). The use of glucocorticoids was observed in 47.4% of patients and there was a significant tendency of lower use of these drugs in the presence of dyslipidemia (PR: 0.790; p = 0.007). We observed that the presence of cardiovascular comorbidities was associated with higher use of bDMARDs (PR:1.147; p = 0.003). The presence of cardiovascular risk comorbidities was confirmed to be higher in RA patients. Different treatment strategies using less glucocorticoids in the presence of dyslipidemia and more common use of bDMARDs in patients with cardiovascular comorbidities suggest that rheumatologists are aware of the potential influence of the DMARDs in the risk of cardiovascular event. Reinforcing these results, we highlight the need for a better baseline assessment to guide the choice of anti-rheumatic drugs in RA patients who have comorbidities.
Tài liệu tham khảo
Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Prim [Internet]. 2018;4:1800 [acesso em 2020 ago 14]. Disponível em: https://doi.org/10.1038/nrdp.2018.1.
World Health Organization (WHO). Chronic rheumatic conditions. 2019 [acesso em 2020 ago 18]; Disponível em: https://www.who.int/chp/topics/rheumatic/en/.
Myasoedova E, Davis JM, Crowson CS, Gabriel SE. Epidemiology of rheumatoid arthritis: rheumatoid arthritis and mortality. Curr Rheumatol Rep. 2010;12(5):379–85. https://doi.org/10.1007/s11926-010-0117-y.
Aletaha D, Smolen JS. Diagnosis and Management of Rheumatoid Arthritis: a review. JAMA. 2018;320(13):1360–72. https://doi.org/10.1001/jama.2018.13103.
Baghdadi LR, Woodman RJ, Shanahan EM. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS One. 2015;10(2):e0117952. https://doi.org/10.1371/journal.pone.0117952.
Radner H, Lesperance T, Accortt NA, Solomon DH. Incidence and prevalence of cardiovascular risk factors among patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis. Arthritis Care Res. 2017;69(10):1510–8. https://doi.org/10.1002/acr.23171.
Myasoedova E, Gabriel SE, Matteson EL, Davis JM 3rd, Therneau TM, Crowson CS. Decreased cardiovascular mortality in patients with incident rheumatoid arthritis (RA) in recent years: dawn of a new era in cardiovascular disease in RA? J Rheumatol. 2017;44(6):732–9. https://doi.org/10.3899/jrheum.161154.
Blum A, Adawi M. Rheumatoid arthritis (RA) and cardiovascular disease. Autoimmun Rev. 2019;18(7):679–90. https://doi.org/10.1016/j.autrev.2019.05.005.
England BR, Thiele GM, Anderson DR, Mikuls TR. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ. 2018;361:1–17.
Semb AG, Ikdahl E, Wibetoe G, Crowson C, Rollefstad S. Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. Nat Rev Rheumatol [Internet]. 2020;16(7):361–79 [acesso em 2020 out 18]. Disponível em: http://dx.doi.org/10.1038/s41584-020-0428-y.
da Mota LMH, Kakehasi AM, Gomides APM, Duarte ALBP, Cruz BA, Brenol CV, et al. 2017 recommendations of the Brazilian Society of Rheumatology for the pharmacological treatment of rheumatoid arthritis. Adv Rheumatol. 2018;58(1):1–17.
Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2016;68(1):1–25. https://doi.org/10.1002/acr.22783.
Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJL, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2016;76(1):17–28. https://doi.org/10.1136/annrheumdis-2016-209775.
Gualtierotti R, Ughi N, Marfia G, Ingegnoli F. Practical management of cardiovascular comorbidities in rheumatoid arthritis. Rheumatol Ther. 2017;4(2):293–308. https://doi.org/10.1007/s40744-017-0068-0.
Pereira IA, Mota LM, Cruz BA, Brenol CV, Fronza LS, Bertolo MB, et al. 2012 Brazilian Society of Rheumatology Consensus on the management of comorbidities in patients with rheumatoid arthritis. Rev Bras Reumatol. 2012;52(4):474–95.
Nurmohamed MT, Heslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol. 2015;11(12):693–704. https://doi.org/10.1038/nrrheum.2015.112.
Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480–9. https://doi.org/10.1136/annrheumdis-2014-206624.
Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):S685–99.
da Rocha C-PG, Vargas-Santos AB, de Albuquerque CP, Bértolo MB, Júnior PL, Giorgi RDN, et al. The REAL study: a nationwide prospective study of rheumatoid arthritis in Brazil. Adv Rheumatol. 2018;58(1):9.
Hutchinson D. Classification criteria: the 1987 American rheumatism association revised criteria for the classification of rheumatoid arthritis. CPD Rheumatol. 1999;1(1):13–4.
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81. https://doi.org/10.1002/art.27584.
Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância de Doenças e Agravos não Transmissíveis e Promoção da Saúde. Vigitel Brasil 2017: Vigilância de fatores de risco e proteção para doenças crônicas por inquérito telefônico: estimativas sobre frequência e distribuição sociodemográfica de fatores de risco e de proteção para doenças crônicas nas capitais dos 26 estados brasileiros e no Distrito Federal em 2017 [recurso eletrônico]. Brasília: Ministério da Saúde, 2017. [acesso em 2020 fev 25]. Disponível em: https://bvsms.saude.gov.br/bvs/publicacoes/vigitel_brasil_2017_vigilancia_fatores_riscos.pdf.
Acosta-Mérida Á, Naranjo A, Rodríguez-Lozano C. Prognostic Factors for Sustained Remission in a “Real Life” Cohort of Rheumatoid Arthritis Patients. Reumatol Clin [Internet]. 2020;16(5Pt2):405–9 [acesso em 2020 set 07]. Disponível em: https://doi.org/10.1016/j.reuma.2018.10.002.
Wilson JC, Sarsour K, Gale S, Pethö-Schramm A, Jick SS, Meier CR. Incidence and risk of glucocorticoid-associated adverse effects in patients with rheumatoid arthritis. Arthritis Care Res. 2019;71(4):498–511. https://doi.org/10.1002/acr.23611.
Lee JL, Sinnathurai P, Buchbinder R, Hill C, Lassere M, March L. Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study. Arthritis Res Ther. 2018;20(1):1–9.
Balsa A, Lojo-Oliveira L, Alperi-López M, García-Manrique M, Ordóñez-Cañizares C, Pérez L, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring in clinical practice: the spanish cohort of the COMORA study. Reumatol Clin. 2019;15(2):102–8. https://doi.org/10.1016/j.reuma.2017.06.002.
Crowson CS, Rollefstad S, Ikdahl E, Kitas GD, Van Riel PLCM, Gabriel SE, et al. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2018;77(1):48–54. https://doi.org/10.1136/annrheumdis-2017-211735.
Myasoedova E, Chandran A, Ilhan B, Major BT, Michet CJ, Matteson EL, et al. The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease. Ann Rheum Dis. 2016;75(3):560–5. https://doi.org/10.1136/annrheumdis-2014-206411.
Humphreys JH, Warner A, Chipping J, Marshall T, Lunt M, Symmons DP, et al. Mortality trends in patients with early rheumatoid arthritis over 20 years: results from the Norfolk arthritis register. Arthritis Care Res. 2014;66(9):1296–301. https://doi.org/10.1002/acr.22296.
Singh S, Fumery M, Singh AG, Singh N, Prokop LJ, Dulai PS, et al. Comparative risk of cardiovascular events with biologic and synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res. 2020;72:561–76.
Burggraaf B, Van Breukelen-Van Der Stoep DF, De Vries MA, Klop B, Liem AH, Van De Geijn GJM, et al. Effect of a treat-to-target intervention of cardiovascular risk factors on subclinical and clinical atherosclerosis in rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2018:335–41.
del Rincon I, Battafarano DF, Restrepo JF, et al. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum. 2014;66(2):264–72. https://doi.org/10.1002/art.38210.
Cardiel MH, Pons-Estel BA, Sacnun MP, Wojdyla D, Saurit V, Marcos JC, et al. Treatment of early rheumatoid arthritis in a multinational inception cohort of Latin American patients: the GLADAR experience. J Clin Rheumatol. 2012;18(7):327–35. https://doi.org/10.1097/RHU.0b013e31826d6610.
Nissen SE, Yeomans ND, Solomon DH, Lüscher TF, Libby P, Husni ME, et al. PRECISION trial investigators. Cardiovascular safety of Celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375(26):2519–29. https://doi.org/10.1056/NEJMoa1611593.
Lindhardsen J, Gislason GH, Jacobsen S, Ahlehoff O, Olsen AMS, Ole Rintek Madsen, et al. Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis. 2014;73(8):1515–21. https://doi.org/10.1136/annrheumdis-2012-203137.
Johnson TM, Mikuls TR, England BR. Assessment of cardiovascular disease risk in rheumatoid arthritis. J Clin Outcomes Manag. 2019;26(1):41–7.
Giollo A, Bissell LA, Buch MH. Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review. Expert Opin Drug Saf [Internet]. 2018;17(7):697–708 [acesso em 2020 set 07]. Disponível em: https://doi.org/10.1080/14740338.2018.1483331.
Radner H, Yoshida K, Hmamouchi I, Dougados M, Smolen JS, Solomon DH. Treatment patterns of multimorbid patients with rheumatoid arthritis: results from an international cross-sectional study. J Rheumatol. 2015;42(7):1099–104. https://doi.org/10.3899/jrheum.141534.
Low ASL, Symmons DPM, Lunt M, Mercer LK, Gale CP, Watson KD, et al. Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76(4):654–60. https://doi.org/10.1136/annrheumdis-2016-209784.
Kang EH, Jin Y, Brill G, Lewey J, Patorno E, Desai RJ, et al. Comparative cardiovascular risk of Abatacept and tumor necrosis factor inhibitors in patients with rheumatoid arthritis with and without diabetes mellitus: a multidatabase cohort study. J Am Heart Assoc. 2018;7:e007393.
Jin Y, Kang EH, Brill G, Desai RJ, Kim SC. Cardiovascular (CV) risk after initiation of Abatacept versus TNF inhibitors in rheumatoid arthritis patients with and without baseline CV disease. J Rheumatol. 2018;45(9):1240–8. https://doi.org/10.3899/jrheum.170926 Epub 2018 May 15. PMID: 29764964.
Nurmohamed M, Choy E, Lula S, Kola B, DeMasi R, Accossato P. The impact of biologics and tofacitinib on cardiovascular risk factors and outcomes in patients with rheumatic disease: a systematic literature review. Drug Saf. 2018;41(5):473–88. https://doi.org/10.1007/s40264-017-0628-9.